• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interactions between primidone, carbamazepine, and nicotinamide.

作者信息

Bourgeois B F, Dodson W E, Ferrendelli J A

出版信息

Neurology. 1982 Oct;32(10):1122-26. doi: 10.1212/wnl.32.10.1122.

DOI:10.1212/wnl.32.10.1122
PMID:6214728
Abstract

The effect of nicotinamide on the conversion of primidone to phenobarbital was studied in mice and in three epileptic patients. In mice, 200 mg per kilogram of nicotinamide increased the half-life of primidone by 47.6%, and the conversion to phenobarbital and phenylethylmalonamide was decreased by 32.4% and 14.5%, respectively. Nicotinamide also decreased the conversion of primidone to phenobarbital in patients. The dose of nicotinamide correlated directly with the primidone-phenobarbital ratio (r = 0.861, p less than 0.01). Nicotinamide also increased carbamazepine levels in two patients treated with this drug. The data demonstrate that nicotinamide inhibits metabolism of primidone in mice and metabolism of primidone and carbamazepine in humans. This probably occurs by inhibition of cytochrome P-450 by nicotinamide.

摘要

相似文献

1
Interactions between primidone, carbamazepine, and nicotinamide.
Neurology. 1982 Oct;32(10):1122-26. doi: 10.1212/wnl.32.10.1122.
2
Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers.
Eur J Clin Pharmacol. 1980 Jul;18(1):31-42. doi: 10.1007/BF00561476.
3
Phenylethylmalonamide serum levels in patients treated with primidone and the effects of other antiepileptic drugs.
Ther Drug Monit. 1986;8(2):161-5. doi: 10.1097/00007691-198606000-00006.
4
The effect of phenytoin and ethosuximide on primidone metabolism in patients with epilepsy.
J Neurol. 1975 Jun 9;209(2):115-23. doi: 10.1007/BF00314604.
5
Phenytoin: an inhibitor and inducer of primidone metabolism in an epileptic patient.苯妥英:一名癫痫患者中扑米酮代谢的抑制剂和诱导剂。
Br J Clin Pharmacol. 1982 Aug;14(2):294-7. doi: 10.1111/j.1365-2125.1982.tb01980.x.
6
Carbamazepine levels in pregnancy and lactation.孕期及哺乳期的卡马西平血药浓度
Obstet Gynecol. 1979 Jan;53(1):139-40.
7
Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery.对考虑进行癫痫手术的患者,系统测试卡马西平、苯妥英钠、苯巴比妥或扑米酮单药治疗的医学难治性。
Epilepsia. 1996 Jul;37(7):675-9. doi: 10.1111/j.1528-1157.1996.tb00632.x.
8
[The effect of monotherapy on concentration of selected blood serum hormones and upon cognitive function of children with epilepsy].[单一疗法对癫痫患儿血清特定激素浓度及认知功能的影响]
Endokrynol Pol. 1992;43(2 Suppl):1-66.
9
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.卡马西平、苯巴比妥、苯妥英和扑米酮在部分性发作及继发性全面性强直-阵挛发作中的比较。
N Engl J Med. 1985 Jul 18;313(3):145-51. doi: 10.1056/NEJM198507183130303.
10
Disposition of primidone, phenylethylmalonamide, and phenobarbital in the rabbit.
Drug Metab Dispos. 1978 Jan-Feb;6(1):75-81.

引用本文的文献

1
Biological Efficacy and Safety of Niacinamide in Patients With ADPKD.烟酰胺对常染色体显性多囊肾病患者的生物学疗效及安全性
Kidney Int Rep. 2020 Jun 10;5(8):1271-1279. doi: 10.1016/j.ekir.2020.06.002. eCollection 2020 Aug.
2
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.卡马西平具有临床意义的药代动力学药物相互作用。最新进展。
Clin Pharmacokinet. 1996 Sep;31(3):198-214. doi: 10.2165/00003088-199631030-00004.
3
Antiepileptic drugs. A review of clinically significant drug interactions.抗癫痫药物。具有临床意义的药物相互作用综述。
Drug Saf. 1993 Sep;9(3):156-84. doi: 10.2165/00002018-199309030-00003.
4
Anticonvulsant drugs. An update.抗惊厥药物。最新进展。
Drugs. 1984 Apr;27(4):328-63. doi: 10.2165/00003495-198427040-00003.